首頁 > 市場調查報告書 > 製藥

疫苗基因治療學和RNAi

市場調查報告書

商品編碼

1481828

全球 mRNA 疫苗市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global mRNA Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月06日 | 出版商:

Value Market Research | 英文 126 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球mRNA疫苗市場需求預計將從2023年的222.3億美元達到2032年近137.3億美元的市場規模，2024-2033年研究期間的複合年成長率為-5.21%。

mRNA 疫苗使用信使 RNA (mRNA) 分子來指導體內細胞製造蛋白質，從而刺激針對特定病原體（例如病毒或細菌）的免疫反應。這些疫苗將編碼病毒或細菌抗原的合成 mRNA 序列傳遞到細胞中，將其轉化為觸發免疫反應的蛋白質抗原。它們不含活病原體，比傳統疫苗更安全，並且可以快速開發和生產以應對新出現的傳染病。這些疫苗在預防 COVID-19 等傳染病的臨床試驗中顯示出有希望的結果，並且正在研究其在治療癌症和其他疾病方面的潛在應用。

市場動態

應對 COVID-19 大流行的迫切需求加速了 mRNA 疫苗的研究、開發和部署，作為預防病毒感染的一種有前途的方法。 mRNA 疫苗，例如 Pfizer-BioNTech 和 Moderna COVID-19 疫苗，在臨床試驗和現實世界研究中取得了很高的療效，可以快速預防 SARS-CoV-2 感染和嚴重的 COVID-19 疾病。此外，與傳統疫苗技術相比，這些疫苗具有多種優勢，包括更快的開發時間、可擴展性以及對新興變種的適應性。此外，應對 COVID-19 大流行的成功引發了人們對各種傳染病的興趣和投資，包括流感、愛滋病毒、茲卡病毒和呼吸道合胞病毒 (RSV)。此外，這些疫苗的潛在應用範圍不僅限於傳染病，還包括癌症免疫治療，其中 mRNA 疫苗可以加速免疫系統識別和靶向腫瘤細胞，為個人化癌症治療提供了一種有前途的方法。此外，製造合作夥伴關係、技術轉移協議和產能擴張計劃的出現正在加速這些疫苗的全球生產和分銷，以滿足不斷成長的需求並應對供應鏈挑戰。然而，替代疫苗技術的出現以及對長期功效和安全性的擔憂可能會挑戰未來幾年的市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球 mRNA 疫苗市場的各個細分市場進行了包容性評估。 mRNA 疫苗產業的成長和趨勢為本研究提供了整體方法。

市場區隔

mRNA 疫苗市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按申請

新冠肺炎
其他

按最終用戶

政府機構
私立醫院及診所
其他（藥局等）

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲 mRNA 疫苗市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。 mRNA疫苗市場的主要參與者包括輝瑞公司、Moderna Inc.、諾華公司、賽諾菲、Arcturus、Gennova Biopharmaceuticals Ltd.、艾美疫苗有限公司。、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展等動態。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：mRNA 疫苗公司的競爭格局

mRNA疫苗市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Moderna Inc.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Arcturus

公司簡介
公司收入
產品
最近的發展

Gennova Biopharmaceuticals Ltd.

公司簡介
公司收入
產品
最近的發展

Aimei Vaccine Co. Ltd

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114452

The global demand for mRNA Vaccine Market is presumed to reach the market size of nearly USD 13.73 Billion by 2032 from USD 22.23 Billion in 2023 with a CAGR of -5.21% under the study period 2024-2033.

mRNA vaccines use messenger RNA (mRNA) molecules to instruct cells in the body to make proteins that stimulate an immune response against specific pathogens, such as viruses or bacteria. These vaccines deliver synthetic mRNA sequences encoding viral or bacterial antigens into cells, translating them into protein antigens that trigger an immune response. They do not contain live pathogens, making them safer than traditional vaccines, and they can be rapidly developed and produced in response to emerging infectious diseases. These vaccines have demonstrated promising results in clinical trials for preventing infectious diseases such as COVID-19 and are being investigated for their potential applications in treating cancer and other diseases.

MARKET DYNAMICS

The urgent need to tackle the COVID-19 pandemic has accelerated the research, development, and deployment of mRNA vaccines as a promising approach to preventing viral infections. mRNA vaccines, such as the Pfizer-BioNTech and Moderna COVID-19 vaccines, have resulted in high efficacy in clinical trials and real-world studies, offering rapid protection against SARS-CoV-2 infection and severe COVID-19 disease. Additionally, these vaccines provide several advantages over traditional vaccine technologies, including faster development timelines, scalability, and adaptability to emerging variants of concern. Moreover, the success in addressing the COVID-19 pandemic has sparked interest and investment in various infectious diseases, including influenza, HIV, Zika virus, and respiratory syncytial virus (RSV). Furthermore, the potential applications of these vaccines extend beyond infectious diseases to include cancer immunotherapy, where mRNA vaccines can accelerate the immune system to recognize and target tumor cells, offering a promising approach to personalized cancer treatment. Additionally, the emergence of manufacturing partnerships, technology transfer agreements, and capacity expansion initiatives is accelerating global production and distribution of these vaccines to meet growing demand and address supply chain challenges. However, the emergence of alternative vaccine technologies and concerns about long-term efficacy and safety may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of mRNA Vaccine. The growth and trends of mRNA Vaccine industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the mRNA Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

COVID-19
Others

By End-user

Government Entities
Private Hospitals & Clinics
Others (Pharmacies etc.)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the mRNA Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the mRNA Vaccine market include Pfizer Inc., Moderna Inc., Novartis AG, Sanofi, Arcturus, Gennova Biopharmaceuticals Ltd., Aimei Vaccine Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MRNA VACCINE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By End-user
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MRNA VACCINE MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data
5.3. Analysis By Application
5.4. COVID-19 Historic and Forecast Sales By Regions
5.5. Others Historic and Forecast Sales By Regions

6. GLOBAL MRNA VACCINE MARKET ANALYSIS BY END-USER

6.1. Overview By End-user
6.2. Historical and Forecast Data
6.3. Analysis By End-user
6.4. Government Entities Historic and Forecast Sales By Regions
6.5. Private Hospitals & Clinics Historic and Forecast Sales By Regions
6.6. Others (Pharmacies etc.) Historic and Forecast Sales By Regions

7. GLOBAL MRNA VACCINE MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE MRNA VACCINE COMPANIES

8.1. MRNA Vaccine Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF MRNA VACCINE INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Pfizer Inc.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Moderna Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Novartis AG
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Sanofi
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Arcturus
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Gennova Biopharmaceuticals Ltd.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Aimei Vaccine Co. Ltd
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments